Bevacizumab therapy for tamoxifen-induced crystalline retinopathy and severe cystoid macular edema

Arch Ophthalmol. 2012 Jul;130(7):931-2. doi: 10.1001/archophthalmol.2011.2741.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Astrocytoma / drug therapy
  • Astrocytoma / surgery
  • Bevacizumab
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / surgery
  • Estrogen Antagonists / adverse effects*
  • Humans
  • Intravitreal Injections
  • Macular Edema / chemically induced
  • Macular Edema / diagnosis
  • Macular Edema / drug therapy*
  • Male
  • Retinal Diseases / chemically induced
  • Retinal Diseases / diagnosis
  • Retinal Diseases / drug therapy*
  • Tamoxifen / adverse effects*
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Estrogen Antagonists
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Tamoxifen
  • Bevacizumab